Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia (PROSTO)

Pfizer logo

Pfizer

Status

Terminated

Conditions

Community-Acquired Pneumonia

Treatments

Drug: Azithromycin SR
Drug: Amoxiclav

Study type

Observational

Funder types

Industry

Identifiers

NCT01032694
A0661200

Details and patient eligibility

About

To compare compliance between patients with CAP treated with Azithromycin SR 2.0 g single dose orally and those treated with Amoxiclav - 1000 mg twice daily 10 days for the empiric treatment of CAP in outpatient clinic practice.

Enrollment

30 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Males or not pregnant or lactating females, 18 years of age or older, for whom oral antibacterial therapy is indicated with clinically evidence of Diagnosis of pneumonia, based on usual clinical practice:

  • Physical examination and auscultatory findings (dullness on percussion, bronchial breath sounds, egophony, dry or fine most rales).
  • Body temperature >38 degrees C.

Exclusion criteria

  • Known or suspected hypersensitivity or intolerance or contraindications to Azithromycin.
  • Amoxiclav according to LPDs, pregnant or lactating women.

Trial design

30 participants in 2 patient groups

Z-max treated group
Description:
Patients with Community-Acquired Pneumonia
Treatment:
Drug: Azithromycin SR
Amoxiclav treated group
Description:
Patients with Community-Acquired Pneumonia
Treatment:
Drug: Amoxiclav

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems